| 重组人脑利钠肽在低LVEF值心脏瓣膜置换手术患者围术期的应用分析 |
| |
| 引用本文： | 刘慧,郭松林,王云,宋艳艳. 重组人脑利钠肽在低LVEF值心脏瓣膜置换手术患者围术期的应用分析[J]. 心脏杂志, 2022, 34(3): 325-328. DOI: 10.12125/j.chj.202111016 |
| |
| 作者姓名： | 刘慧 郭松林 王云 宋艳艳 |
| |
| 作者单位： | 1.药剂科 宁夏医科大学总医院 |
| |
| 基金项目： | 2021年宁夏自治区科技厅社会发展领域重点研发项目资助（2021BEG03070）；2021年宁夏自治区科技厅社会发展领域重点研发项目资助（2021BEG03070） |
| |
| 摘 要： | 目的 探讨在低LVEF值瓣膜置换手术患者围术期应用重组人脑利钠肽的效果及临床意义。 方法 选取宁夏医科大学总医院心脏大血管外科2020年6月～2021年10月共70例LVEF≤50 %行瓣膜置换术患者，随机分为对照组和观察组，每组35例。对照组采取标准抗心衰药物治疗，观察组在标准抗心衰药物治疗的基础上加用重组人脑利钠肽治疗，比较两组患者围术期心功能恢复相关指标:NT-proBNP、尿量、LVEF值、FS值及左心室舒末内径变化，并进行统计学分析。 结果 两组患者术前临床指标比较无统计学差异，观察组用药后24 h和72 h NT-proBNP水平下降（P<0.05），用药后24 h和72 h尿量增加（P<0.01）；呼吸机使用时间及ICU时间缩短，与对照组相比较均有显著性差异（P<0.05）。但两组血肌酐水平无显著性差异，临床结局（并发症、治愈、死亡）无统计学意义。 结论 低LVEF值瓣膜置换术患者围术期应用重组人脑利钠肽有利于术后心功能恢复，缩短呼吸机使用时间及ICU时间，但对血肌酐水平无影响。
|
| 关 键 词： | 重组人脑利钠肽 心脏瓣膜置换术 围术期 |
| 收稿时间： | 2021-11-03 |
Perioperative analysis of recombinant human brain natriuretic peptide in patients undergoing cardiac valve replacement with low left ventricular ejection fraction value |
| |
| Affiliation: | 1.Department of Pharmacy2.Stem Cell Research Institute3.Department of Cardiovascular Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia, China |
| |
| Abstract: | AIM To investigate the perioperative effect and clinical significance of recombinant human brain natriuretic peptide in valve replacement surgery for patients with low left ventricular ejection fraction (LVEF) valve. METHODS Seventy patients with LVEF≤50% who underwent valve replacement surgery in our hospital from June 2020 to October 2021 were randomly divided into control group and observation group, with 35 cases in each group. The control group was treated with standard anti-heart failure drugs and the observation group was treated with recombinant human brain natriuretic peptide on the basis of standard anti-heart failure drugs. The perioperative cardiac function recovery related indicators (NT-proBNP, urine volume, LVEF value, FS value and changes of left ventricular end-diastolic diameter) in the two groups were compared and statistical analysis was conducted. RESULTS There was no statistical difference in preoperative clinical indicators between the two groups. The level of NT-proBNP in observation group decreased 24 h and 72 h after medication, and urine volume increased 24 h and 72 h after medication. The duration of ventilator use and ICU were shortened and there were significant differences compared with those in control group (P<0.01). However, there was no significant difference in serum creatinine level between the two groups and the clinical outcomes (complication, cure and mortality) were not statistically significant. CONCLUSION Perioperative use of recombinant human brain natriuretic peptide in valve replacement surgery for patients with low LVEF value is beneficial to postoperative cardiac function recovery, shortens the duration of ventilator use and ICU, but has no effect on serum creatinine level. |
| |
| Keywords: | |
|
| 点击此处可从《心脏杂志》浏览原始摘要信息 |
|
点击此处可从《心脏杂志》下载免费的PDF全文 |
|
